- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01715623
Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies. (PRIERR)
The investigators previously showed that both antibody class switching (from IgM to IgG, IgA or IgE) and antibody secretion are controlled by a polymorphic "3' regulatory region" (3'RR) of the immunoglobulin heavy chain (IgH) locus. Alleles of the 3'RR have shown influences on the severity and progression of IgA nephropathy (IgAN) (with an over-representation of the B allele among patients with severe kidney IgA deposits). Allele B also constitutes a risk factor for celiac disease, herpetiform dermatitis, psoriasis and rheumatoid arthritis. Since the 3'RR now appears as a crucial regulator of Ig production, we wish to check whether its genetic polymorphism might influence not only the occurrence of immunopathologic processes involving class-switched antibody deregulated production but also the severity of such diseases or the time course of their progression. We wish to focus on two conditions involving class-switched antibodies: on one hand the severe forms of IgE hypersensitivities, and on the other hand a disease involving pathogenic IgA and for which the prognosis is currently very difficult to predict at the onset of the disease: Henoch-Schonlein purpura (HSP).
Regarding hypersensitivities, the diversity of their clinical manifestations prompt us to focus on homogeneous groups of patients and we thus wish to concentrate on two groups of patients who are frequently referred to the hospital: severe allergies to Hymenoptera venoms and severe food allergies related to peanut allergens sensitization. These groups will be built by considering multiple clinical criteria (clinical history, severity of the manifestations, positive skin tests, and positive oral provocation tests for peanut allergens…) and biological criteria authenticating the mechanisms of the disease (high specific serum IgE, demonstration of specific basophil activation by the allergen…).
In parallel to the study in patients, we will include a large cohort of healthy controls (400 individuals), in order to be able to decipher whether correlations can be seen between:
- IgH 3'RR genotypes
- The serum accumulation of the various Ig classes, including IgG subclasses, IgA (which are sometimes depicted as protective, sometimes as tolerogenic and anti-inflammatory) and IgE (highly pro-inflammatory and responsible for hypersensitivities)
- IgG allotypes (with 6 frequent IgG haplotypes known in human and previously reported as correlated with varying levels of IgG and IgE production in normal individuals).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study should thus finally provide answers to 5 questions which are currently un-addressed:
- How the 3'RR alleles are linked to IgG allotypes and corresponding IgH haplotypes?
- Is there a physiological link between 3'RR alleles and production of the various Ig classes and sub-classes?
- Is the 3'RR polymorphism connected with the risk of more severe forms of allergic diseases?
- Is the 3'RR polymorphism connected with the risk of occurrence and/or severe evolution of HSP?
- Is the oncogenicity of translocations affecting the IgH locus connected to the strength of the 3'RR allelic variants?
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Limoges, France, 87042
- Clinical Investigation Center
-
Limoges, France, 87042
- Nephrology
-
Limoges, France, 87042
- Pediatric
-
Limoges, France, 87042
- Pneumology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
4 populations :
- Healthy Volunteers
- subjects with HPS
- subjects with peanut allergy or hymenoptera venom allergy
- lymphoma (biological collection)
La description
Inclusion Criteria:
- Healthy Volunteers:
Age ≥ 18 and < 50 years No history of allergy, haematological malignancies or immune diseases
- Subjects with allergy:
- Children:
Age ≥ 4 and < 18 years Clinical history supporting the diagnosis of severe food allergy Peanut specific IgE (Arah2) -Adults: Age > 18 and < 60 years History of severe reaction after antigenic challenge Anaphylactic shock already experienced Specific IgE or positive BAT Positive prick tests
- subject with HPS:
- Children:
Age ≥ 4 and < 18 years Henoch Schonlein Purpura (HSP) documented by Ankara 2008 criteria
-Adult: Henoch Schonlein Purpura(HSP) with renal involvement Adults ≥ 18 years,
Exclusion Criteria:
- subject with allergy or subject with Henoch Schonlein Purpura(HSP): known pregnancy patient under guardianship
- Healthy Volunteers:
Allergy known pregnancy patient under guardianship
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Children with HSP
children with Purpura of Henoch-Schönlein with or without renal complication
|
Dosage of Ig
|
|
healthy volunteers
healthy volunteers without allergy
|
Dosage of Ig
|
|
subjects with allergy
subjects with peanut allergy or hymenoptera venom allergy
|
Dosage of Ig
|
|
lymphoma
lymphoma-proliferation with chromosome 14 translocation
|
Dosage of Ig
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
the percentage of allele B
Délai: one day
|
A comparison will be made of the percentage of allele B between healthy volunteers and the three cohorts of subjects with various diseases: (1) lymphoma (lymphoma-proliferation with chromosome 14 translocation ), (2) Henoch-Schonlein purpura HSP (3), allergy (peanut and Hymenoptera venom)
|
one day
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Michel COGNE, MD, Limoges UH
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- I12002 PRIERR
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .